Related Experiment Videos
Nongastric mucosa-associated lymphoid tissue lymphomas
Catherine Thieblemont1, Arnaud de la Fouchardière, Bertrand Coiffier
1Hematology Department, Hospices Civils de Lyon, Université Claude Bernard, Lyon, France.
Clinical Lymphoma
|April 4, 2003
Summary
Nongastric mucosa-associated lymphoid tissue (MALT) lymphomas present indolently, often disseminating to non-mucosal sites. Survival rates are favorable, with treatment tailored to localized or disseminated disease.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Nongastric mucosa-associated lymphoid tissue (MALT) lymphomas originate from diverse extranodal sites.
- Disease pathogenesis is often linked to external factors like environmental or autoimmune triggers.
Purpose of the Study:
- To analyze the clinical features of nongastric MALT lymphomas.
- To evaluate survival and progression rates in patients with nongastric MALT lymphoma.
Main Methods:
- Retrospective review of 165 patients with nongastric MALT lymphoma.
- Analysis of clinical presentation, disease dissemination, and treatment outcomes.
- Literature review to supplement patient data.
Main Results:
- Nongastric MALT lymphomas typically present indolent clinical features.
- Disease dissemination occurred in 48% of cases, involving mucosal or non-mucosal sites.
- Estimated 5-year survival was 89% and freedom-from-progression was 50%, irrespective of disease stage or location.
Conclusions:
- Treatment strategies vary for localized (surgery, local therapy, chlorambucil) versus disseminated disease (chemotherapy regimens like fludarabine, chlorambucil, or CHOP).
- Nongastric MALT lymphoma demonstrates a generally favorable prognosis despite potential dissemination.